3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Lung Neoplasms
2
Brain Neoplasms
2
Respiratory Tract Diseases
1
Neoplasms
1
Meningeal Carcinomatosis
1
Interventions
Gefitinib
3
Erlotinib Hydrochloride
3
sotorasib
1
pralsetinib
1
osimertinib
1
ficlatuzumab
1
exemestane
1
entinostat
1
durvalumab
1
cobimetinib
1
camrelizumab
1
Tyrosine Kinase Inhibitors
1
Radiosurgery
1
Prednisone
1
Pemetrexed
1
Leuprolide
1
Dasatinib
1
Carboplatin
1
Afatinib
1
AZD3759
1
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Respiratory Tract Diseases
×
AZD3759
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled